Alternatively, significant differences in CCL20 expression were detected in 14 cancers, with significantly higher expression in breast invasive carcinoma, CHOL, glioblastoma multiforme, COAD, ESCA, HNSC, READ, STAD, KIRC, thyroid carcinoma (THCA), LIHC, LUAD, and uterine corpus endometrial carcinoma, and significantly lower expression in KICH (Supplementary Fig. S4A). Here, CCL20 is linked to uterine corpus endometrial carcinoma.